Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07287163 | Clinical Trial of Vormatrigine in Adult Patients With Epilepsy | PHASE3 | ENROLLING BY_INVITATION | 700 | — | — | Oct 27, 2025 | Dec 31, 2028 | Dec 17, 2025 | 20 | United States, Germany +3 |
Incidence and severity of TEAEs including discontinuation of study drug due to TEAEs
| Arm | Type | Description |
|---|---|---|
| Open-label 30 mg/day vormatrogine for up to 2 years | EXPERIMENTAL | Participants who meet all eligibility criteria will receive 30 mg of vormatrogine for up to 2 years. |
| Name | Type | Description |
|---|---|---|
| vormatrogine | DRUG | Once daily oral |
Inclusion Criteria: * Participant who completed an eligible clinical trial (unless agreed by the sponsor medical monitor), including PRAX-628-212, PRAX-628-321 or other vormatrigine trials, or participant who has received vormatrigine outside of an eligible clinical trial (such as an expanded acces...